News

Call to Action – NIH Technology Accelerator Challenge for Maternal Health – up to $1 Million in Cash Prizes!

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is proud to announce the launch of the NIH Technology Accelerator Challenge for Maternal Health (NTAC: Maternal Health) in conjunction with the White House Maternal Health Day of Action. 

NTAC: Maternal Health is offering up to $1,000,000 in cash prizes to reward the development of low-cost, point-of-care molecular, cellular, and/or metabolic sensing and diagnostic technologies to guide rapid clinical decision-making, improve patient outcomes, and ultimately prevent maternal morbidity and mortality. More broadly, the NTAC series of prize competition’s goals are to stimulate the design of new diagnostic technologies to transform public and global health and accelerate the full development of those products urgently needed for use in low-resource settings. Device prototypes submitted to NTAC: Maternal Health should be capable of full integration with digital health platforms and be able to diagnose at least two pregnancy-associated conditions, including infections, hypertensive disease, hemorrhage, or placental issues. Complete challenge details can be found at https://www.nibib.nih.gov/research-program/NIH-Technology-Accelerator-Challenge-Maternal-Health-Announcement .

Participants in NTAC: Maternal Health will compete for the first-place prize of up to $500,000, a second-place prize of up to $300,000, and a third-place prize of up to $150,000, with the potential for additional awards of $50,000 for semi-finalists as well as honorable mention recognitions. Additionally, the Bill & Melinda Gates Foundation is collaborating with NIH and will separately review winners and honorable mentions to consider them for follow-on support that may include grant funding and/or in-kind support in the form of consultations and partnerships for clinical data collection, software development, scale-up, and manufacturing. This Challenge is also co-sponsored by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the NIH Office of Research on Women’s Health.

The Challenge sponsors will host an Informational Webinar for any interested participants on January 13, 2022, from 12:00 pm-1:00 pm ET. Participants wishing to compete in NTAC: Maternal Health must register for the Challenge by April 1, 2022, at https://venturewell.org/ntac/. Submissions will begin to be accepted on January 5, 2022, and must be submitted by April 22, 2022. In case of any questions, send an email to NIBIBChallenge@mail.nih.gov .

Recent News

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and

06/02/2026

Contraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive into Late-Stage Development

Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, today announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. In conjunction with the closing of the Series B financing,

06/02/2026

GEN Names BioHealth Capital Region a Top 3 U.S. Biopharma Cluster for Fourth Year in a Row

The BioHealth Capital Region, spanning Maryland, Virginia, and Washington, D.C., has once again been named one of the nation’s Top 3 biopharma clusters by Genetic Engineering & Biotechnology News (GEN), marking the region’s fourth consecutive year in the Top 3. GEN’s 2026 “Top 10 U.S. Biopharma Clusters” ranking was authored by Alex Philippidis, Senior Business